Boris Pasche
Overview
Explore the profile of Boris Pasche including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
2931
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharma S, Wu S, Jimenez H, Xing F, Zhu D, Liu Y, et al.
EBioMedicine
. 2024 Dec;
111():105541.
PMID: 39731855
No abstract available.
2.
Agyemang K, Johansen A, Barker G, Pennison M, Sheffield K, Jimenez H, et al.
NPJ Breast Cancer
. 2022 Jul;
8(1):84.
PMID: 35853889
There is growing evidence that germline mutations in certain genes influence cancer susceptibility, tumor evolution, as well as clinical outcomes. Identification of a disease-causing genetic variant enables testing and diagnosis...
3.
Su J, Huang L, Barnard R, Parks G, Cappellari J, Bellinger C, et al.
Front Oncol
. 2021 May;
11:584896.
PMID: 33937015
The (C2Dx) is a promising solution to address the need for a molecular pathological research and diagnostic tool for precision oncology utilizing small volume tumor specimens. We translate subtyping-related gene...
4.
Su J, Song Q, Qasem S, ONeill S, Lee J, Furdui C, et al.
Front Oncol
. 2021 Apr;
10:615472.
PMID: 33889540
Background: The incidence of brain metastasis continues to increase as therapeutic strategies have improved for a number of solid tumors. The presence of brain metastasis is associated with worse prognosis...
5.
Sirkisoon S, Carpenter R, Rimkus T, Doheny D, Zhu D, Aguayo N, et al.
Oncogene
. 2021 Mar;
40(12):2338.
PMID: 33654200
No abstract available.
6.
Jatoi A, Ou F, Ahn D, Zemla T, Le-Rademacher J, Boland P, et al.
Oncologist
. 2021 Feb;
26(7):610-618.
PMID: 33604969
Background: Hand-foot skin reaction (HFSR) is the most common regorafenib-induced adverse event and is in need of effective prevention and palliation. Materials And Methods: The Regorafenib Dose Optimization Study (ReDOS),...
7.
Steber C, Hughes R, McTyre E, Soike M, Farris M, Levine B, et al.
Cureus
. 2021 Feb;
13(1):e12574.
PMID: 33575139
Purpose To determine the efficacy and toxicity of two standard chemotherapy regimens used concurrent with radiation for the treatment of esophageal cancer: cisplatin/5-fluorouracil (5-FU) and carboplatin/paclitaxel. Materials and methods We...
8.
Liu L, Ahmed T, Petty W, Grant S, Ruiz J, Lycan T, et al.
Mol Oncol
. 2020 Oct;
15(2):462-472.
PMID: 33107184
KRAS is a key oncogenic driver in lung adenocarcinoma (LUAD). Chromatin-remodeling gene SMARCA4 is comutated with KRAS in LUAD; however, the impact of SMARCA4 mutations on clinical outcome has not...
9.
Cai Z, Li C, Han F, Liu C, Zhang A, Hsu C, et al.
Mol Cell
. 2020 Oct;
80(2):263-278.e7.
PMID: 33022274
Cancer metastasis accounts for the major cause of cancer-related deaths. How disseminated cancer cells cope with hostile microenvironments in secondary site for full-blown metastasis is largely unknown. Here, we show...
10.
Jimenez H, Sharma S, Sheffield K, Agyemang K, Johansen A, Blackman C, et al.
Int J Radiat Biol
. 2020 Apr;
96(7):845-846.
PMID: 32223577
No abstract available.